Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib

Podobne zapisy

• The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib
  od: Buder, Anna, i wsp.
  Wydane: (2020)
• Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
  od: Yamamoto, Nobuyuki, i wsp.
  Wydane: (2019)
• EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib
  od: Buder, Anna, i wsp.
  Wydane: (2020)
• Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients
  od: Hackner, Klaus, i wsp.
  Wydane: (2021)
• Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
  od: Zöchbauer-Müller, Sabine, i wsp.
  Wydane: (2021)